Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 20

Results For "Director"

2827 News Found

Wanbury achieves first sales invoicing and commercial shipment milestone
News | February 04, 2026

Wanbury achieves first sales invoicing and commercial shipment milestone

This achievement validates global demand and catapults Wanbury into high-growth acceleration


Lupin & TB Alliance team up to push groundbreaking TB drug forward
News | February 03, 2026

Lupin & TB Alliance team up to push groundbreaking TB drug forward

TB Alliance will continue to lead clinical development, while Lupin will leverage its global manufacturing, regulatory, and supply chain expertise to ensure the drug reaches patients worldwide


Indoco Remedies bags USFDA nod for Lacosamide oral solution
News | February 02, 2026

Indoco Remedies bags USFDA nod for Lacosamide oral solution

The approved Lacosamide Oral Solution is bioequivalent and therapeutically equivalent to the reference drug and will be manufactured at Indoco’s facility in Verna Industrial Area, Goa


Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan
Policy | February 01, 2026

Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan

The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave


Glenmark reports robust Q3 FY26 performance, revenues surge 15% YoY
News | January 31, 2026

Glenmark reports robust Q3 FY26 performance, revenues surge 15% YoY

rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million


Wanbury unveils API facility in Tanuku, targets Rs. 100 crore revenue
News | January 30, 2026

Wanbury unveils API facility in Tanuku, targets Rs. 100 crore revenue

The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules


Vimta Labs reports 10% YoY growth in Q3 FY26, PAT margins hold at 17.5%
News | January 30, 2026

Vimta Labs reports 10% YoY growth in Q3 FY26, PAT margins hold at 17.5%

The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year


Cupid gets certification for HIV & Hepatitis B test kits, paving way for global expansion
News | January 29, 2026

Cupid gets certification for HIV & Hepatitis B test kits, paving way for global expansion

The newly certified kits are designed for early detection and large-scale screening programs


Granules India consolidated Q3 FY26 PAT rises to Rs. 150.21 Cr
News | January 25, 2026

Granules India consolidated Q3 FY26 PAT rises to Rs. 150.21 Cr

Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025